Literature DB >> 35102373

Smoking Behaviour Changes After Diagnosis of Inflammatory Bowel Disease and Risk of All-cause Mortality.

Xinwei Hua1,2, Emily W Lopes1,2, Kristin E Burke1,2, Ashwin N Ananthakrishnan1,2, James M Richter1, Chun-Han Lo1,3, Paul Lochhead1,2, Andrew T Chan1,2,4, Hamed Khalili1,2,5,6.   

Abstract

BACKGROUND AND AIMS: We examined smoking behaviour changes after diagnoses of Crohn's disease [CD] and ulcerative colitis [UC] and evaluated their impact on mortality.
METHODS: Study population included incident CD or UC cases from three cohorts of the Nurses' Health Study [NHS], NHSII, and Health Professionals Follow-up Study. Smoking and other risk factors were prospectively assessed. Smoking behaviour changes were categorised as never, former [i.e., quit smoking before diagnosis], quitters [i.e., quit smoking after diagnosis], and current [i.e., continue smoking after diagnosis]. Follow-up for date and cause of death was completed through linkage to the National Death Index. Cox proportional hazard regression was used to estimate hazard ratios [HRs] and 95% confidence intervals [CIs].
RESULTS: Among 909 eligible CD and UC cases, 45% were never smokers, 38% were past smokers, and 16% were active smokers at the time of diagnosis. Among active smokers, 70% of patients with CD and 44% of patients with UC continued to smoke after diagnosis. In patients with CD, compared with current smokers, the multivariable-adjusted HRs [95% CI] of death were 0.19 [0.10 to 0.38] for never smokers, 0.31 [0.16 to 0.57] for former smokers, and 0.41 [0.18 to 0.93] for quitters. Similarly for UC, compared with current smokers, we observed a reduced risk of mortality for never smokers [HR = 0.23, 95% CI 0.10 to 0.51], former smokers [HR = 0.23, 95% CI 0.11 to 0.48], and quitters [HR = 0.28, 95% CI 0.11 to 0.72].
CONCLUSIONS: In three cohorts of health professionals, a substantial proportion of patients with new diagnosis of CD and UC and history of smoking continued to smoke after diagnosis. Smoking cessation around the time of diagnosis was associated with a significant reduction in mortality.
© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Inflammatory bowel disease; behaviour change; mortality; smoking

Mesh:

Year:  2022        PMID: 35102373      PMCID: PMC9351977          DOI: 10.1093/ecco-jcc/jjac015

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   10.020


  49 in total

1.  A meta-analysis of the role of smoking in inflammatory bowel disease.

Authors:  B M Calkins
Journal:  Dig Dis Sci       Date:  1989-12       Impact factor: 3.199

2.  Effects of current and former cigarette smoking on the clinical course of Crohn's disease.

Authors:  J Cosnes; F Carbonnel; F Carrat; L Beaugerie; S Cattan; J Gendre
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

3.  Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis.

Authors:  O Höie; L J Schouten; F L Wolters; I C Solberg; L Riis; I A Mouzas; P Politi; S Odes; E Langholz; M Vatn; R W Stockbrügger; B Moum
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

4.  Crohn's disease and smoking: is it ever too late to quit?

Authors:  Ian C Lawrance; Kevin Murray; Birol Batman; Richard B Gearry; Rachel Grafton; Krupa Krishnaprasad; Jane M Andrews; Ruth Prosser; Peter A Bampton; Sharon E Cooke; Gillian Mahy; Graham Radford-Smith; Anthony Croft; Katherine Hanigan
Journal:  J Crohns Colitis       Date:  2013-06-20       Impact factor: 9.071

5.  The Nurses' Health Study: 20-year contribution to the understanding of health among women.

Authors:  G A Colditz; J E Manson; S E Hankinson
Journal:  J Womens Health       Date:  1997-02       Impact factor: 2.681

6.  Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire.

Authors:  D Feskanich; E B Rimm; E L Giovannucci; G A Colditz; M J Stampfer; L B Litin; W C Willett
Journal:  J Am Diet Assoc       Date:  1993-07

7.  Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.

Authors:  A Timmer; L R Sutherland; F Martin
Journal:  Gastroenterology       Date:  1998-06       Impact factor: 22.682

8.  Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.

Authors:  Tine Jess; Karen Vanessa Winther; Pia Munkholm; Ebbe Langholz; Vibeke Binder
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

9.  An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease.

Authors:  I D R Arnott; G McNeill; J Satsangi
Journal:  Aliment Pharmacol Ther       Date:  2003-06-15       Impact factor: 8.171

10.  Survival and causes of death in patients with inflammatory bowel disease: a population-based study.

Authors:  A Ekbom; C G Helmick; M Zack; L Holmberg; H O Adami
Journal:  Gastroenterology       Date:  1992-09       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.